Altimmune, Inc. — Director's Dealing 2023

Mar 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-03-23

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-23	Common Stock, par value $0.0001	P	9000	$4.27	Acquired	29484	Indirect

Footnotes

F1: Represents Common Stock purchased and immediately transferred to Pacific Biopharma Associates, LLC.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.265 to $4.28, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Includes 20,151 shares of Common Stock previously owned directly by the reporting person which were transferred to Pacific Biopharma Associates, LLC.

F4: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.